A Study of Alirocumab in Participants With Autosomal Dominant Hypercholesterolemia (ADH) and Gain-of-Function Mutations (GOFm) of the Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Gene or Loss-of-Function Mutations (LOFm) of the Apolipoprotein (Apo) B Gene

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 22, 2012

Primary Completion Date

June 2, 2014

Study Completion Date

July 28, 2017

Conditions

Hypercholesterolemia

Interventions

DRUG

Alirocumab

SC injection in the abdomen

DRUG

Placebo

SC injection in the abdomen

Trial Locations (4)

Salt Lake City

Lille

Nantes

Paris